Published in Nature on October 24, 2012
Cancer genome landscapes. Science (2013) 25.33
The Reactome pathway knowledgebase. Nucleic Acids Res (2013) 8.56
Whole genomes redefine the mutational landscape of pancreatic cancer. Nature (2015) 4.01
Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science (2016) 3.45
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun (2014) 3.12
Genomic analyses identify molecular subtypes of pancreatic cancer. Nature (2016) 2.70
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell (2014) 2.50
Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet (2017) 2.42
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet (2015) 2.27
Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol (2014) 2.21
Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res (2015) 2.11
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS One (2016) 2.08
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med (2015) 2.05
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun (2015) 1.94
Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem (2014) 1.92
The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nat Cell Biol (2014) 1.87
Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell (2014) 1.85
KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci (2014) 1.85
Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology (2014) 1.78
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature (2017) 1.72
Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer (2014) 1.71
SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov (2013) 1.68
Targeting mTOR dependency in pancreatic cancer. Gut (2014) 1.65
Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nat Commun (2013) 1.62
Roles for KRAS in pancreatic tumor development and progression. Gastroenterology (2013) 1.61
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet (2014) 1.60
Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet (2013) 1.53
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med (2016) 1.50
An open access pilot freely sharing cancer genomic data from participants in Texas. Sci Data (2016) 1.42
Neat1 is a p53-inducible lincRNA essential for transformation suppression. Genes Dev (2017) 1.39
BRCAness revisited. Nat Rev Cancer (2016) 1.38
The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest (2013) 1.37
Comparing somatic mutation-callers: beyond Venn diagrams. BMC Bioinformatics (2013) 1.35
Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. J Exp Med (2015) 1.35
Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology (2013) 1.34
Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol (2013) 1.34
Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol (2014) 1.33
Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci Adv (2015) 1.33
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun (2015) 1.33
The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res (2014) 1.32
Evolution and dynamics of pancreatic cancer progression. Oncogene (2013) 1.25
Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. Cell Death Differ (2014) 1.25
Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut (2014) 1.23
Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. Am J Clin Pathol (2014) 1.21
Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol (2014) 1.19
microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions. Oncogene (2013) 1.18
A reversible gene trap collection empowers haploid genetics in human cells. Nat Methods (2013) 1.17
Pathway and network analysis of cancer genomes. Nat Methods (2015) 1.17
Targeting DNA damage response in cancer therapy. Cancer Sci (2014) 1.16
TET proteins and the control of cytosine demethylation in cancer. Genome Med (2015) 1.13
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13
Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol (2013) 1.11
Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Rep (2016) 1.11
The small GTPase ARF6 stimulates β-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis. Sci Signal (2013) 1.10
NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes. Database (Oxford) (2014) 1.10
Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell (2013) 1.09
The complex landscape of pancreatic cancer metabolism. Carcinogenesis (2014) 1.08
SF3B1 mutations in chronic lymphocytic leukemia. Blood (2013) 1.08
SF3B1 mutations constitute a novel therapeutic target in breast cancer. J Pathol (2014) 1.07
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet (2016) 1.07
Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights. Clin Cancer Res (2013) 1.07
CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Cancer Immunol Res (2014) 1.06
Inactivating CUX1 mutations promote tumorigenesis. Nat Genet (2013) 1.06
Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers. PLoS Comput Biol (2015) 1.05
A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. Nat Med (2014) 1.05
Genomic landscape of liposarcoma. Oncotarget (2015) 1.04
Mechanisms of genome instability induced by RNA-processing defects. Trends Genet (2014) 1.04
Somatic point mutation calling in low cellularity tumors. PLoS One (2013) 1.03
Optimizing cancer genome sequencing and analysis. Cell Syst (2015) 1.03
WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma. Oncogene (2013) 1.03
The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. Genome Biol (2013) 1.03
Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine. Med Sci Monit (2013) 1.03
SWI/SNF chromatin remodeling complexes and cancer. Am J Med Genet C Semin Med Genet (2014) 1.03
Mutations in NALCN cause an autosomal-recessive syndrome with severe hypotonia, speech impairment, and cognitive delay. Am J Hum Genet (2013) 1.03
Deciphering the role of stroma in pancreatic cancer. Curr Opin Gastroenterol (2013) 1.03
Biopsies: next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol (2013) 1.02
Slit/Robo signaling regulates cell fate decisions in the intestinal stem cell lineage of Drosophila. Cell Rep (2014) 1.02
Advances in pancreatic cancer research: moving towards early detection. World J Gastroenterol (2014) 1.02
Cytosine deamination is a major cause of baseline noise in next-generation sequencing. Mol Diagn Ther (2014) 1.02
Widespread intron retention diversifies most cancer transcriptomes. Genome Med (2015) 1.01
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov (2015) 1.01
Mechismo: predicting the mechanistic impact of mutations and modifications on molecular interactions. Nucleic Acids Res (2014) 1.01
Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Genes Dev (2015) 1.00
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene (2015) 1.00
Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol (2015) 1.00
Stromal reengineering to treat pancreas cancer. Carcinogenesis (2014) 1.00
Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice. Nat Commun (2016) 1.00
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res (2014) 0.99
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Mol Med (2015) 0.99
WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. Biochim Biophys Acta (2014) 0.98
Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer (2016) 0.98
Epigenomic regulation of oncogenesis by chromatin remodeling. Oncogene (2016) 0.97
Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs. J Biol Chem (2013) 0.97
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther (2015) 0.97
Axonal guidance signaling pathway interacting with smoking in modifying the risk of pancreatic cancer: a gene- and pathway-based interaction analysis of GWAS data. Carcinogenesis (2014) 0.96
Therapeutic options for the management of pancreatic cancer. World J Gastroenterol (2014) 0.96
Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep (2015) 0.96
Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Oncotarget (2015) 0.96
The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas. Mol Cancer Res (2015) 0.96
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
International network of cancer genome projects. Nature (2010) 20.35
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 12.35
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65
MuSiC: identifying mutational significance in cancer genomes. Genome Res (2012) 4.73
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer (2002) 3.89
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63
ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
The divergent Robo family protein rig-1/Robo3 is a negative regulator of slit responsiveness required for midline crossing by commissural axons. Cell (2004) 3.19
Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res (2009) 3.09
The role of neuropilins in cancer. Mol Cancer Ther (2006) 2.28
Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol (2009) 1.94
Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg (2008) 1.93
Invasive growth: from development to metastasis. J Clin Invest (2002) 1.91
Novel roles for Slits and netrins: axon guidance cues as anticancer targets? Nat Rev Cancer (2011) 1.84
Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2012) 1.82
The brain within the tumor: new roles for axon guidance molecules in cancers. Cell Death Differ (2005) 1.78
qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS One (2012) 1.77
Semaphorin signaling in cancer cells and in cells of the tumor microenvironment--two sides of a coin. J Cell Sci (2009) 1.74
Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer (2011) 1.54
Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res (2011) 1.47
A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol (2011) 1.34
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 1.32
Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology (2009) 1.27
Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer. Int J Cancer (2007) 1.26
Cancer research: past, present and future. Nat Rev Cancer (2011) 1.24
The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. J Clin Oncol (2012) 1.16
In vitro and in vivo characterization of a novel semaphorin 3A inhibitor, SM-216289 or xanthofulvin. J Biol Chem (2003) 1.15
Somatic variation and cancer: therapies lost in the mix. Hum Genet (2011) 0.99
Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum Genet (2011) 0.96
A map of human genome variation from population-scale sequencing. Nature (2010) 121.13
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
The Bioperl toolkit: Perl modules for the life sciences. Genome Res (2002) 58.63
The complete genome of an individual by massively parallel DNA sequencing. Nature (2008) 52.81
Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res (2005) 44.08
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science (2007) 37.88
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature (2007) 35.08
Integrating common and rare genetic variation in diverse human populations. Nature (2010) 32.30
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Stem cell transcriptome profiling via massive-scale mRNA sequencing. Nat Methods (2008) 31.04
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Strong association of de novo copy number mutations with autism. Science (2007) 27.84
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52
Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature (2004) 24.40
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A (2002) 20.48
Resolving individuals contributing trace amounts of DNA to highly complex mixtures using high-density SNP genotyping microarrays. PLoS Genet (2008) 20.38
International network of cancer genome projects. Nature (2010) 20.35
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Direct selection of human genomic loci by microarray hybridization. Nat Methods (2007) 17.73
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27